ClinicalTrials.Veeva

Menu

Optimal Protein Supplementation for Critically Ill Patients

University of Oklahoma (OU) logo

University of Oklahoma (OU)

Status

Withdrawn

Conditions

Critical Illness

Treatments

Dietary Supplement: Beneprotein

Study type

Interventional

Funder types

Other

Identifiers

NCT01934595
SCCM Vision (Other Grant/Funding Number)
3440

Details and patient eligibility

About

It is well accepted that during critical illness there is an increase in protein breakdown and loss of lean body mass. Previous studies have shown that during critical illness muscle breakdown increases dramatically. The aim of our study is to test the hypothesis that critically ill patients have improved outcomes with higher protein supplementation.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • • Medical or surgical patients who are admitted or transferred to the ICU with an APACHE II score greater than or equal to 18 and who are candidates for enteral nutrition within 48 hours of admission.

Exclusion criteria

  • • Patients who cannot tolerate enteral nutrition

    • Patients who have a contraindication for enteral nutrition per American Society of Enteral and Parenteral Nutrition guidelines (GI obstruction, intractable nausea and/or vomiting, short bowel syndrome, distal GI fistula, GI bleeding that will require endoscopy, malabsorption that requires TPN, inability to access the GI tract
    • Patients with chronic stage III or IV kidney disease and/or patients receiving dialysis within six months of this hospital admission as these patients are known to require specific protein diets as an outpatient. Patients with acute kidney injury will not be excluded as there is no evidence to suggest these patients require a specific protein diet secondary to their acute kidney injury.
    • Patients with refractory hypotension unresponsive to vasoactive medications
    • Patients who are unlikely to survive the next 48 hours at the time of enrollment (this will be judged by the treating physician)
    • Patients who are unable to give consent and do not have a family member able to give consent on his/her behalf.
    • Patients with end stage liver disease or undergoing liver transplant or liver resection surgery
    • Patients whose physician thinks he/she should not participate
    • Prisoners
    • Pregnant women (all female of childbearing age will have a urine pregnancy test prior to randomization)

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

0 participants in 2 patient groups

Varying amounts of Beneprotein
Experimental group
Description:
1.5grams/kg/day, 2.0 grams/kg/day, and 2.5 grams/kg, day
Treatment:
Dietary Supplement: Beneprotein
1 Gram - Standard Therapy given in ICU
Active Comparator group
Description:
1 gram/kg/day of protein
Treatment:
Dietary Supplement: Beneprotein

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems